The global microbial bioreactor market was valued at USD 696.7 million in 2019 and is forecasted to reach USD XX million by 2027, with a CAGR of 6.0% during the forecast period (2020-2027).
Microbial bioreactor is a vessel designed to carry out biological reactions and used to culture aerobic cells for conducting cellular and enzymatic immobilization. They provide tissue-specific physiology in the tissue environment during tissue maturation. It is a core of biochemical processes in which enzymes, microbial, mammalian or plant cells are used for manufacturing of a wide range of biological products. These systems are culture systems used in the production of cells and organisms. These are used in various applications from research & development, manufacturing of biopharmaceuticals to food & food additives and chemicals. Generally, microbial bioreactor is maintained aerobically, or alternating aerobic/anaerobic phases to enhance the microbial nitrification followed by denitrification.Growing implementation/inclusion of microbial cells and organisms in the production of biopharmaceuticals, food and food additives, and other research activities are driving the global microbial bioreactor market during forecast period. Global microbial bioreactor market is consolidated with 4-5 major players occupying significant market share, and the rest of the large group of companies. The market is experiencing new technological innovations, product launches in portable and highly effective microbial bioreactors.In May 2019, Sartorius Stedium Biotech launched a new ambr 15 cell culture micro bioreactor system that significantly reduces cell line development timelines and increased lab productivity. Some of the key players in the global microbial bioreactor market include Sartorius AG, GE Healthcare Life Sciences, Merck KGaA, Pall Corporation, among many others.
Market Dynamics
Driver
- Growing pharmaceutical and biologics industry
- Increasing demand for personalized medicines
Restraints
- Low Capacity of bioreactors
Opportunities
- Growing demand for orphan drugs developments
- Technological advancements in Microbial Bioreactor
Growing demand for orphan drugs developments
- Growing demand for orphan drugs developments is a major opportunity driving the global microbial bioreactor market. The orphan drugs require microbial bioreactors for production of specific biologics catering specific demands.
- Incentives for developing orphan drugs, The financial incentives and overall rewards for the successful development of drugs for the treatment and diagnosis of rare diseases and conditions are significant, and as such companies are motivated to design commercially viable end-products to obtain such benefits.
Technological advancements in Microbial Bioreactor
- Technological advancements in the field of microbial bioreactor has evolved as an effective opportunity, and enhanced the market.
- Many industry players entered into the market with innovative types of bioreactors in the last few years.
- The advancements in the bioreactors led to the faster and easier production of bio-products, which also reduced the cost of the production.
Geographical Analysis
The Europe microbial bioreactor Market is valued at US$ 194.3 Million in 2019 and is estimated to grow at a CAGR of 6.1% over the forecast period to reach US$ XX Million by 2028. Europe microbial bioreactor market accounted for a cumulative revenue of USD 2,033.2 million between 2019 and 2026. Europe accounted for a market share of 27.9% in global microbial bioreactor in 2018 and expected to reach 28.1% by 2026.UK, Germany and many other developed nations countries across Europe are dominating the Europe microbial bioreactor market owing to the high presence of research & development laboratories across the globe coupled with significant rise in investments by the respective companies to boost the development of novel drugs through microbial bioreactors. According to the study published in European Federation of Pharmaceutical Industries and Associations, the R&D expenditure by the pharmaceutical companies located across the European Union increased from USD 38.362 billion in 2017 to USD 41.536 billion in 2018. The inclusion of advanced technologies such as photobioreactors for the production of sustainable plants and bioreactors for the production of cultured meat are major factors expected to boost the demand for microbial bioreactors across the region during the forecast period. Rising investment by the food giants towards sustainable business models for future, and abilities by the communities across the region to adapt to the changes are expected to further boost the demand for microbial bioreactor in Europe during forecast period. The food and beverages companies have their research and development bases across the region, and growing presence of CMO & CDMO in the biopharmaceutical industry are further boosting the Europe microbial bioreactor market during forecast period.
About Us:
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.
For more information:
Sai Kiran
Sales Manager at DataM Intelligence
Email: info@datamintelligence.com
Tel: +1 877 441 4866
Website: www.datamintelligence.com
